Showing 1851-1860 of 4063 results for "".
- Moderna Secures FDA Approval to Advance Coronavirus Vaccine Candidate mRNA-1273 to Phase 2 Testinghttps://modernod.com/news/moderna-secures-fda-approval-to-advance-coronavirus-vaccine-candidate-mrna-1273-to-phase-2-testing/2477729/Moderna said the FDA is allowing it to move ahead with a phase 2 study of its experimental COVID-19 vaccine mRNA-1273. Moderna stated that it will begin the study with 600 participants “shortly” and is finalising the protocol for a phase 3 trial to start early this summer, with CEO St
- Oculis to Present Results From Its Phase 2 Trial of OCS-01 for Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-to-present-results-from-its-phase-2-trial-of-ocs-01-for-inflammation-and-pain-following-cataract-surgery/2477721/Oculis announces that it will present results from its phase 2 (SKYGGN) clinical trial, evaluating the efficacy and safety of its drug candidate OCS-01 for the treatment of inflammation and pain following cataract surgery, at the American Society of Cataract and Refractive Surgery (ASCRS) annual
- GenSight Biologics Announces Positive Safety Review of PIONEER Phase 1/2 Trial of Retinitis Pigmentosa Treatmenthttps://modernod.com/news/gensight-biologics-announces-positive-safety-review-of-pioneer-phase-1-2-trial-of-retinitis-pigmentosa-treatment/2477583/GenSight Biologics announced that the independent Data Safety Monitoring Board (DSMB) completed its second planned safety review of the ongoing PIONEER phase 1/2 clinical trial of GS030, GenSight’s novel product combining gene therapy and optogenetics for the treatment of retinitis pigmentosa (RP
- Pfizer Aims to Start Clinical Testing of Lead Compound Against SARS-CoV-2 in Third Quarterhttps://modernod.com/news/pfizer-aims-to-start-clinical-testing-of-lead-compound-against-sars-cov-2-in-third-quarter/2477560/In an update on its efforts to combat COVID-19, Pfizer said results of initial screening assays have led it to zero in on a lead protease inhibitor with antiviral activity against SARS-CoV-2 based on preliminary data. The company stated that it will now perform preclinical testing on the compound
- Vazegepant, Investigational Drug Being Studied for Migraine, to Enter Phase 2 Trial for COVID-19 Treatmenthttps://modernod.com/news/vazegepant-investigational-drug-being-studied-for-migraine-to-enter-phase-2-trial-for-covid-19-treatment/2477557/The FDA has authorized initiation of a phase 2 trial of vazegepant (Biohaven, New Haven, CT) for potential treatment of COVID-19 pulmonary complications. Vazegepant is an intranasally delivered calcitonin gene-related peptide (CGRP) inhibitor antagonist in phase 3 trials for the treatment of migr
- Nicox’s End-of-Phase 2 Meeting With the FDA Sets Stage for NCX 470 Phase 3 Program in Glaucomahttps://modernod.com/news/nicoxs-end-of-phase-2-meeting-with-the-fda-sets-stage-for-ncx-470-phase-3-program-in-glaucoma/2477350/Nicox announced that it has successfully completed an end-of-phase 2 meeting with the FDA and agreed on the design for the NCX 470 phase 3 program, as well as nonclinical and CMC plans supporting submission of a new drug application (NDA) in the U.S. NCX 470, a novel second generation nitric oxid
- Ribomic Announces First Injection in the Phase 2 Clinical Trial of RBM-007 (TOFU Study) in Subjects with Wet AMDhttps://modernod.com/news/ribomic-announces-first-injection-in-the-phase-2-clinical-trial-of-rbm-007-tofu-study-in-subjects-with-wet-amd/2477304/Ribomic announced that first patient has received injection in the phase 2 trial of RBM-007 for the treatment of wet age-related macular degeneration (AMD) in the United States. The first site started enrollment at the end of December 2019 and five sites are now active across the United States.</
- Oculis Announces Positive OCS-01 Phase 2 Data in Patients with Diabetic Macular Edema (DME)https://modernod.com/news/oculis-announces-positive-ocs-01-phase-2-data-in-patients-with-diabetic-macular-edema-dme/2477287/Oculis reported positive data from a phase 2 study of OCS-01, a novel eye drop formulation of dexamethasone, in development for the treatment of diabetic macular edema (DME), according to a company news release. OCS-01 was developed using Oculis’ proprietary Soluble NanoParticle technolog
- Nicox to Present NCX 470 Phase 2 Results at Glaucoma 360 New Horizons Forumhttps://modernod.com/news/nicox-to-present-ncx-470-phase-2-results-at-glaucoma-360-new-horizons-forum/2477281/Nicox SA today announced that Tomas Navratil, PhD, Executive Vice President, Head of R&D of Nicox group, and General Manager of Nicox Ophthalmics, Inc, will present results from the NCX 470 Dolomites phase 2 clinical trial in the session “New Horizons in Pharmaceuticals” at the Glaucoma 360 N
- Neuroptika Announces Enrollment Of First Patient In Phase 2 Clinical Trial For Dry Eye Diseasehttps://modernod.com/news/neuroptika-announces-enrollment-of-first-patient-in-phase-2-clinical-trial-for-dry-eye-disease/2477235/Neuroptika announced that the first patient was enrolled in a phase 2 clinical trial of NRO-1 for the treatment of dry eye disease. NRO-1 is a novel therapeutic with the potential to protect and regenerate corneal nerves in ophthalmic diseases. “Existing treatments for dry eye diseas